A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China (UNMASK2)

Novartis

Status

Completed

Conditions

Psoriasis

Treatments

Drug: secukinumab

Study type

Observational

Funder types

Industry

Identifiers

NCT04894890

CAIN457ACN06

Details and patient eligibility

About

This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and without PsA) initiating treatment of secukinumab.

Full description

All patients will be followed up for 52 weeks no matter they adhere to secukinumab or they have shifted to other treatment plans. Data will be collected in conjunction with routine care visits, most likely happen at week 0, 4, 12, 16, 24, 36, 52. No extra study visits, examinations, laboratory tests or procedures will be mandated. If visits happen at other time points (not within the window period), then they will be counted as unscheduled visits.

Enrollment

1,002 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aged ≥ 18 years;
Diagnosis of clinically moderate to severe plaque-psoriasis;
Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date;
Patient agrees to sign the informed consent

Exclusion criteria